Bayer’s Stock Waits on a Judicial Verdict While Asundexian Opens a Regulatory Door
16.06.2026 - 02:54:52 | boerse-global.de
Bayer shares are stuck in a narrow groove. At €36.23, the stock is hovering barely above its 200-day moving average of €36.03, having shed about 27% from its February high of €49.93. The relative strength index sits at 46.8 — neutral territory, but tellingly flat. This is not a company that investors are eager to bet on, even as its pipeline delivers tangible progress and its cost-cutting machine hums along.
On June 10, the European Medicines Agency accepted Bayer’s filing for Asundexian, an oral factor XIa inhibitor designed to prevent ischemic strokes in adults after a non-cardioembolic event. The application, backed by a global trial involving over 12,000 participants, marks the first submission of its drug class in Europe. The U.S. Food and Drug Administration has already granted priority review, and applications are pending in China and Japan. The clinical logic is compelling: after Asundexian failed in atrial fibrillation two years ago, it came back strongly in the secondary prevention setting — and Bayer now holds a regulatory lead over its main rival, Bristol Myers Squibb and Johnson & Johnson’s Milvexian. That lead is a genuine competitive advantage that the market has so far priced lightly.
The strategic weight behind Asundexian is existential, not merely aspirational. Xarelto, Bayer’s blockbuster anticoagulant, saw its revenue collapse by a third to $2.6 billion last year as patent protection crumbled. Asundexian is the designated replacement. Without it, the pharma division’s margin faces a structural gap. The stakes could hardly be higher.
Should investors sell immediately? Or is it worth buying Bayer?
Yet no matter how bright the clinical picture, the immediate share-price anchor is legal. In the first quarter of 2026 alone, Bayer recorded net outflows of over €2 billion, mostly tied to PCB and glyphosate litigation. The dividend for 2025 was slashed to €0.11 per share — a direct consequence of the cash drain. The company has offered a buyout known as the Roundup settlement programme, capped at $7.25 billion, which saw its opt-out deadline pass on June 4 in Missouri. CEO Bill Anderson has warned that final clarity will take “several more weeks”, with a court hearing scheduled for July to approve the deal.
But the real game-changer is the U.S. Supreme Court. In the case known as “Durnell”, the justices will decide a fundamental question: can a company be found liable under state law for a product that the federal EPA has deemed safe? Roughly 80% of the remaining glyphosate claims would be affected by this ruling. A verdict in Bayer’s favour could effectively dissolve the litigation overhang without further settlement costs. Berenberg puts the odds of a favourable outcome at 60% — barely better than a coin toss. The wide dispersion in analyst targets reflects this uncertainty. Berenberg itself lifted its price objective slightly to €40.50, citing improved pharma profitability, while UBS remains far more bullish with a €52 buy rating, supported by external legal assessments.
Operationally, the business is in decent shape. First-quarter net profit came in at €2.81 per share on revenue of €13.41 billion, beating expectations in both pharma and the crop science unit. The restructuring is on track: six layers of management have been eliminated, the executive ranks reduced by two-thirds, and savings of €700 million in 2024 and €800 million in 2025 realised. The target is €2 billion in sustainable cost cuts by the end of 2026. But these efficiencies are not translating into free-cash-flow growth as long as legal settlements continue to bleed cash.
The profile is asymmetric — for better or worse. A Supreme Court win combined with a low opt-out rate in the Roundup settlement would open the door to a genuine revaluation. Without that outcome, the underlying operational strength will remain locked behind legal costs. The next few weeks will determine the stock’s direction more powerfully than any earnings report possibly could.
Ad
Bayer Stock: New Analysis - 16 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
